With the demonstration of excellent survival after liver transplantation (LT), the demand for liver allografts has quickly outpaced the supply, and has generated a persistent gap between organ supply and patient demand. Despite the 2002 implementation of Model for End-Stage Liver Disease (MELD) score allocation, which allowed for allocation to address medical need through objective criteria, there remains geographic inequity because patients in certain donor service areas (DSAs) receive a deceased donor liver transplant before their sicker counterparts in other DSAs. 1 These geographic differences in deceased donor organ availability within the United States shape the current clinical practice of LT, as exemplified by the increased use of living donor liver transplants in highly competitive regions, 2 as well as the increased use of imported liver grafts and extended donor criteria liver grafts. [3] [4] [5] Another approach to address the growing waitlisted population, pursued by candidates located in competitive DSAs, is multiple listing (ML). These candidates undergo evaluation and listing at another center located in a different DSA that allocates transplants at lower MELD scores and with shorter waiting times.
Multiply listed LT candidates have only been characterized previously in the pre-MELD era. 6 From 1997 to 2000, 3.3% of all liver candidates were listed at >1 center. Since then, there have been extensive changes in liver allocation policy, including the application of MELD and the subsequent "Share 15" provision, [7] [8] [9] which have sought to allocate liver allografts more equitably. To date, there does not exist an examination of ML practices for LT candidates during the MELD era of allocation. We hypothesize that the persistent geographic disparities drive some patients to continue to ML at centers located in DSAs with shorter waitlist times, thereby redistributing the waitlisted population. We sought to characterize MELD-era ML candidates, including those who receive a transplant (ML-LT) and those who do not receive a transplant (ML-NT), comparing them with singly listed candidates (SL) at the DSA and regional level, as well as investigate the donor population used. Comparison with single listing Demographic and clinical characteristics of SL and ML (both ML-NT and ML-LT) patients were described with frequency (percent) and median (interquartile range [IQR] ). Distance in miles between primary and secondary listing centers was calculated using the centroid of the ZIP code for each center. Characteristics of SL vs ML and ML-NT vs ML-LT were compared using chisquare and Wilcoxon rank sum tests, as appropriate.
METHODS
Donor service areaelevel characteristics and calculation of donor service area time to transplantation Median match MELD and median Donor Risk Index (DRI) scores for ML patients at both their primary and secondary listing DSAs were analyzed. Differences in these median values were calculated for each ML patient. The signed-rank test determined if the difference in median MELD and DRI scores between primary and secondary DSAs were significantly different from 0.
We estimated the time from listing until 25% of waitlist candidates received transplants within the DSA by year of listing using the Kaplan-Meier method per Merion and colleagues. 6 Time on the waiting list was defined as the number of days from listing to transplantation, with patients who did not receive transplants censored at waitlist removal or last follow-up. In 6 DSAs, 25% of their waitlist did not receive transplants for 1 calendar year (range 18% to 24% of waitlist received transplants). For the latter 6 DSAs, we imputed the number of days from listing to the last censored observation, slightly underestimating the time to LT of the 25% of waitlisted candidates for the DSA.
Odds of multiple listing
The likelihood of ML was evaluated by logistic regression. Demographic and clinical characteristics with p < 0.1 in univariate comparisons were evaluated in multivariate models. Final model covariates were selected with backward elimination using p > 0.05 for exclusion from the model.
Post-transplantation survival
Graft survival was estimated using the Kaplan-Meier method and compared between SL and ML with the log-rank test. Survival time was measured in years from transplantation to the earliest of death, retransplantation, 
Regional comparison
The percentage of listings exported from and imported to each region was assessed as a percent of the total listings per region. We classified ML patients as exported listings in the region of primary listing and imported listings in the region of secondary listing. Export percentages were subtracted from import percentages to determine net export (negative values) and net import (positive values) regions. To assess whether UNOS regions remained independently associated with ML after adjusting for disease severity, inter-regional comparisons were performed using region 8 as the reference region because it represented the region with the lowest net change between importing and exporting of candidates. All statistical analyses were conducted with SAS software (version 9.3, SAS Institute, Inc).
The study was deemed exempt by the Massachusetts General Hospital Institutional Review Board.
RESULTS
During the 7-year study period, there were 58,199 SL and 1358 (2.3%) ML candidates. The percentage of ML candidates remained stable between 2005 and 2011 (mean 2.6% MLs per year; p trend ¼ 0.84), but increased between 2009 to 2011 (from 2.2% to 3.0%; p trend ¼ 0.001) (Fig. 1 ). For ML candidates, median age at initial listing was 54 years (IQR 48 to 60 years). The most common cause of liver disease was HCV (36%), followed by cholestatic liver disease (16%), and alcoholic cirrhosis (11.9%) ( Table 1) .
Primary vs secondary donor service area of listing for multiply listed candidates Comparison of primary and secondary DSA characteristics for ML candidates elucidated the rationale to pursue ML as a strategy to expedite LT. Although the median match MELD score was 26 (IQR 23 to 27) at the primary DSA, the median match MELD was 22 (IQR 22 to 25) at the secondary DSA (p < 0.001). Median time required for 25% of all waitlisted patients to receive a transplant was 120 days (IQR 51 to 170 days) at the primary DSA and 39 days (IQR 21 to 103 days) at the secondary DSA (p < 0.001). Finally, the DRI at the primary vs secondary DSA was statistically different but clinically similar (median 1.39 [IQR 1.33 to 1.47] vs median 1.37 [IQR 1.32 to 1.45]; p < 0.001).
Multiply listed candidates vs singly listed candidates Multiply listed compared with SL candidates were more often male (70.6% vs 66.2%; p ¼ 0.001), white (80.5% vs 70.9%; p < 0.001), blood type O (51.8% vs 46.1%; p < 0.001), nondiabetic (80.6% vs 74.7%; p < 0.001), college educated (55.5% vs 39.0%; p < 0.001), and privately insured (75.6% vs 58.9%, p < 0.001) ( Table 1) . Although the prevalence of HCV diagnosis was similar between ML and SL candidates (35.9% vs 36.4%; p ¼ 0.71), ML candidates were less likely to have alcoholic cirrhosis (11.9% vs 16.1%; p < 0.001), nonalcoholic steatohepatitis (5.7% vs 7.3%; p ¼ 0.02), and hepatocellular carcinoma (6.4% vs 9.4%; p < 0.001), but more frequently had cholestatic liver disease (16% vs 9.8%; p < 0.001) and metabolic liver disease/biliary atresia (11.9% vs 8.2%; p < 0.001). Singly listed candidates, when compared with ML candidates, were more likely to have ascites (74.6% vs 68.9%; p < 0.001) and encephalopathy (59.5% vs 51.8%; p < 0.001), and to require dialysis (5.0% vs 1.6%; p < 0.001) and have exception points (15.1% vs 9.2%; p < 0.001). (Fig. 2A) . For ML candidates, secondary listing occurred at a median of 243 days (IQR 106 to 538 days) after primary listing, at a median MELD score of 16 (IQR 12 to 21), and for a median of 86 days (IQR 26 to 246 days) ( Table 1) . Of the 1,358 ML candidates, 918 (67.6%) ultimately underwent LT (ML-LT), and 30,612 (52.6%) of SL candidates underwent LT. In our study population, significantly more SL candidates (19%) were removed from the waitlist due to reasons coded as "death" and "too sick for transplant" when compared with ML candidates (13%) (p < 0.001). This remained true for waitlist removals coded as "condition improved" (SL 2% and ML 0.9%; p ¼ 0.004).
Multivariate logistic regression model for the odds of ML is presented in Table 2 , with increased odds of ML demonstrated among male, white, blood type O candidates with a college education, private insurance, and without exception points. In addition, there was a higher likelihood of ML for LT candidates with cholestatic liver disease or metabolic liver disease/biliary atresia, but decreased odds of ML for those candidates with diabetes or the need for dialysis. Finally, candidates demonstrated significantly higher odds of pursuing ML as time on the waitlist increased (Fig. 2B ).
Multiply listed candidates: receiving transplants vs not receiving transplants
In comparison with the ML-LT group, patients in the ML group who did not receive transplants (ML-NT) (440 patients [32.4%]) were more often female (33.6% vs 27.3%; p ¼ 0.02) and more likely to lack exception points at primary listing (93.2% vs 81.5%; p 0.001) ( Table 1) . Patients in the ML-NT group, when compared with the ML-LT group, were less likely to be college educated (50.7% vs 57.8%; p ¼ 0.01) and less likely to have private insurance (72.0% vs 77.3%; p ¼ 0.03). In addition, patients in the ML-NT group compared with patients in the ML-LT group appeared to have more evidence of hepatic decompensation, as demonstrated by the considerably higher proportion of patients with encephalopathy and need for dialysis before primary listing (Table 1) .
Although the initial laboratory MELD at primary listing was a median of 14 for both ML-LT and ML-NT, the median laboratory MELD score at the time of secondary listing increased to 17 (IQR 13 to 21) for the ML-LT group, but remained at 14 (IQR 11 to 18) for the ML-NT group (p < 0.001) ( Table 2 ). For the ML-LT group, median DRI was comparable for both primary and secondary listing DSA (data not shown).
Graft survival after LT is shown in Figure 3 . After adjusting for variables significantly associated with graft loss in the Scientific Registry of Transplant Recipients report (see Methods), no difference in post-LT graft survival was detected by ML status vs SL status (hazard ratio ¼ 0.72; 95% CI, 0.46e1.13; p ¼ 0.16) (Fig. 3) . Regional perspective on exporting/importing Net exporters of ML candidates were regions 1, 2, 5, 7, and 9; net importers were regions 3, 4, 6, 8, 10, and 11 (Fig. 4) . After adjusting for disease severity and demographic factors, the likelihood of ML remained significantly associated with UNOS region. Compared with region 8, odds of ML were significantly increased for region 1 (odds ratio [OR] ¼ 1.8; 95% CI, 1.3e2.5), 5 (OR ¼ 1.6; 95% CI, 1.3e2.1), and 9 (OR ¼ 1.5; 95% CI, 1.2e2.0) ( Table 2) .
DISCUSSION
The success of LT has been limited by the number of deceased donors and by the sparse application of living donor LT. The disparity between supply and demand is accentuated by geographic inequity in access to LT. In response to local constraints, clinicians and patients have altered practice patterns with differential rates of marginal liver use, 3, 5 living donor LT, 2 and ML. The differential use of ML across regions has represented a strategy to expedite LT, with migration of patients from areas of poor access to those with improved access.
We demonstrate that a distinct cohort of LT candidates pursue ML to accelerate LT. Multiply listed candidates come disproportionately from regions 1, 5, and 9, broadly recognized as the geographic areas that perform LTs at the highest match MELD scores. Successful ML candidates receive transplants at lower match MELD and need for dialysis, which might allow for the greater capability to migrate to a secondary DSA. However, when compared with successful ML candidates, ML candidates who fail to achieve LT appear to have a greater degree of clinical decompensation, with evidence of more ascites, encephalopathy, and need for dialysis. The latter group represents a component of the liver transplant waitlist that remain underserved because they are unable to undergo LT despite migrating to secondary centers. The previous investigation of ML in LT predates MELD allocation. 6 Between 1997 and 2000, white, male, more educated, privately insured, and blood type O candidates were more likely to pursue ML. Secondary listing sites had mean wait times 109 days shorter than primary listing sites and 77% of ML patients received transplants. 6 Despite the complete reconfiguration of allocation represented by MELD and Share 15 policies, the demographic and socioeconomic profile of the ML candidate has remained constant. A comparable proportion of ML candidates continue to receive transplants at the secondary listing center (76.8% pre-MELD vs 83.6% MELD era). However, MELD ML candidates traveled, on average, 148 miles farther in their pursuit of obtaining a liver transplant when compared with their pre-MELD counterparts.
Another recent analysis relevant to our work examined "inter-DSA travel," defined as candidates who delist at their initial DSA and subsequently relist in a different DSA. 10 Inter-DSA travel candidates emanated predominantly from regions 1, 5, and 11 and shared similar demographic and socioeconomic characteristics as ML candidates. Notably, travel achieved reductions in waitlist mortality. Although at first, inter-DSA travel and ML candidates might appear to be largely overlapping, careful consideration indicates that they are distinct populations. Within our study period, only 253 candidates on the national waitlist fit the inter-DSA travel definition compared with 1,358 candidates who fit the ML definition. In addition, the sequential nature of the 2 listings required for inter-DSA travel compared with the overlapping nature of the 2 listings required for ML suggests that inter-DSA travel might be motivated by reasons other than organ access, including job and/or family relocation. Although the percentage of ML candidates increased significantly during the latter portion of our study period, from 2009 to 2011, ML still represents a small fraction of LT listings. Given current geographic disparity in LT access and the benefit offered by ML, it is surprising that ML is not undertaken more frequently. It might be instructive to specifically query and determine which factorsdpatient, provider, and/or insurerdpose the greatest obstacle(s) to ML. The physical limitations imposed by decompensated end-stage liver disease might present the first and foremost obstacle to broad use of ML. Ironically, we have shown that the waitlisted candidate perhaps best suited for ML from a clinical perspectivedthe compensated cirrhosis patient with hepatocellular carcinomadhas a low likelihood of ML because they are often granted rapid and sure access to deceased donor livers through MELD exception points. This is similar to the decreased use of living donors in this population.
However, as ML remains used by few, and the profile of ML candidates suggests that these few are socioeconomically privileged, then the question is whether ML should continue to exist, a question that has been debated extensively. 6 Abolishing ML might not alter practice substantially, as demonstrated previously when ML for kidney transplantation candidates was banned in New York. 11 In the latter case, although banning ML resulted in a reduction of the overall rate of ML, it did not result in a more equitable and improved access to kidney transplantation. Multiply listed candidates can readily metamorphose into inter-DSA travelers. It is evident that ML represents neither the solution nor the problem, but simply reflects the geographic disparity in liver allocation. Focus should remain on optimizing allocation policy to improve equity in access to deceased donor livers rather than wider promotion and/or propagation of ML, as it is easier for an organ to travel than a patient.
This study is an observational, retrospective review using a national registry database. The assimilated data were not collected for the purpose of investigating ML, which is a limitation of this study. In addition, ML candidates represented only a small fraction (2.3%) of the total waitlist during the study period. To identify and isolate candidates who list at >1 transplantation center with the aim of expediting LT, we excluded those candidates who multiply listed within the same DSA; lacked overlap between their multiple listings; and traveled <50 miles between DSA listings. However, there is no algorithm to capture those patients who traveled to a distant center without first listing at their local center, and we excluded those who delisted before relisting at a secondary centerdthe inter-DSA travelers who have been studied recently. 10 It should be noted that an additional limitation rests in the potential inaccuracies within the UNOS database. Also, the dataset does not characterize a candidate's reason for pursuing ML, or document factors that influence this decision, for example, insurers, transplantation centers, patient finances, or secondary center proximity.
CONCLUSIONS
A discrete subset of LT candidates with distinct racial and socioeconomic characteristics list at multiple transplantation centers in disparate DSAs as a strategy to overcome geographic inequities inherent in access to deceased donor livers to expedite LT. The profile of ML candidates has remained stable for >15 years, despite wide-sweeping changes in allocation policy. Multiple listing, accessible to only a small and select segment of the entire waitlist, yields individual but not communal benefit. As mandated by the Organ Procurement and Transplantation Network Final Rule, 12 which states that nationwide geographic disparities must be minimized, we must continue to develop strategies to better level access to deceased donor livers across regional boundaries. The latter should be carefully explored and pursued, as they can benefit a broad swath of the waitlist and resonate with principles of equity and justice.
